- Home
- CLPR vs ICCM Comparison
CLPR vs ICCM Comparison
Compare CLPR & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- ICCM
- Stock Information
- Founded
- CLPR 2015
- ICCM 2006
- Country
- CLPR United States
- ICCM Israel
- Employees
- CLPR N/A
- ICCM N/A
- Industry
- CLPR Real Estate Investment Trusts
- ICCM
- Sector
- CLPR Real Estate
- ICCM
- Exchange
- CLPR Nasdaq
- ICCM Nasdaq
- Market Cap
- CLPR 57.5M
- ICCM 61.1M
- IPO Year
- CLPR 2017
- ICCM N/A
- Fundamental
- Price
- CLPR $3.92
- ICCM $0.99
- Analyst Decision
- CLPR
- ICCM Strong Buy
- Analyst Count
- CLPR 0
- ICCM 1
- Target Price
- CLPR N/A
- ICCM $2.50
- AVG Volume (30 Days)
- CLPR 60.1K
- ICCM 2.5M
- Earning Date
- CLPR 10-30-2025
- ICCM 11-25-2025
- Dividend Yield
- CLPR 9.79%
- ICCM N/A
- EPS Growth
- CLPR N/A
- ICCM N/A
- EPS
- CLPR N/A
- ICCM N/A
- Revenue
- CLPR $154,103,000.00
- ICCM $2,787,000.00
- Revenue This Year
- CLPR N/A
- ICCM $3.95
- Revenue Next Year
- CLPR N/A
- ICCM $266.15
- P/E Ratio
- CLPR N/A
- ICCM N/A
- Revenue Growth
- CLPR 7.69
- ICCM N/A
- 52 Week Low
- CLPR $3.39
- ICCM $0.48
- 52 Week High
- CLPR $7.12
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- CLPR 45.56
- ICCM 47.07
- Support Level
- CLPR $3.84
- ICCM $0.93
- Resistance Level
- CLPR $4.16
- ICCM $1.40
- Average True Range (ATR)
- CLPR 0.18
- ICCM 0.07
- MACD
- CLPR -0.01
- ICCM -0.01
- Stochastic Oscillator
- CLPR 45.93
- ICCM 12.79
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.